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Abstract 
The I100V isoform of toluene-4-monooxygenase was used to catalyze the oxidative polymerization of anthranil and 
various indoles under mildly acidic conditions, favoring the production of trimers. Compounds produced in sufficient 
yield were purified and tested for their ability to inhibit the growth of B. anthracis, E. faecalis, L. monocytogenes,  
S. aureus, and in some cases, F. tularensis. 15 of the compounds displayed promising antibacterial activity  
(MIC < 5 µg/ml) against one or more of the strains tested, with the best MIC values being <0.8 µg/ml. All of these 
compounds had good selectivity, showing minimal cytotoxicity towards HepG2 cells. The structure was solved for six 
of the compounds that could be crystallized, revealing that minimally two classes of indole based trimers were pro-
duced. One compound class produced was a group of substituted derivatives of the natural product 2,2-bis(3-indolyl) 
indoxyl. The other group of compounds identified was classified as tryptanthrin-like compounds, all having multi-ring 
pendant groups attached at position 11 of tryptanthrin. One compound of particular interest, SAB-J85, had a struc-
ture that suggests that any compound, with a ring structure that can be activated by an oxygenase, might serve as a 
substrate for combinatorial biocatalysis.
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Introduction
A number of Gram-positive bacteria cause, or have the 
potential to cause, significant morbidity and mortality. 
Among these are pathogens that are encountered in the 
broader community and in hospital settings [Staphy-
lococci (Ziakas et  al. 2014), Streptococci (Nygård et  al. 
2014), Enterococci (Rosenberg Goldstein et al. 2014), and 
Clostridia (Goudarzi et al. 2014)] as well as bacteria that 
have the potential for intentional and malicious dispersal 
[Bacillus anthracis and Listeria monocytogenes (NIAID: 
Biodefense and emerging infectious diseases 2015)]. Of 
particular concern are isolates of these organisms that 
have acquired resistance to previously effective antibac-
terial agents. In the USA alone, >2,000,000 people are 
infected with bacteria that are resistant to one or more 
antibiotics, resulting in 23,000 deaths/year (CDC threat 
report 2013). Another significant outcome associated 
with antibacterial resistant infections is the economic 
burden associated with them. The direct cost has been 
estimated to be as high as $20 billion/year, primarily due 
to the fact that treating antibacterial resistant infections 
requires more intensive treatments and longer, more 
costly hospital stays.
The incidence of infection by drug resistant bacte-
rial pathogens varies by location, but overall, appears 
to be on the rise. For example, the prevalence of van-
comycin resistant Enterococcus infections in Chinese 
hospitals went from 0% in 2005 to 4.9% in 2010, which 
is still relatively low, compared to the 18.9% prevalence 
rate found hospitals in Taiwan (Kang and Song 2013). 
A study conducted in the USA found that the preva-
lence of methicillin resistance in Staphylococcus aureus 
(MRSA) increased >3 fold between 2002 and 2007 and 
ultimately MRSA represented 51% of all Staphylococcus 
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infections during the study period (Gerber et  al. 2009). 
The observed MRSA prevalence in the USA falls roughly 
midway between the prevalence of MRSA infection in 
India (22.6%) and that found in Sri Lanka [86.5% (Kang 
and Song 2013)]. While prevalence rates are local, the 
threat of antibacterial resistant pathogens is a world-
wide problem, as resistance that develops in one area can 
rapidly spread to other parts of the globe. This situation 
clearly requires the development of new antibacterial 
compounds to replace the ones that face dwindling effi-
cacy. Though more challenging to produce, antibacterial 
compounds that have novel structures, mechanisms of 
action and/or exploit previously unrecognized targets, as 
compared to those that have already reached the market, 
are the most logical choices for combating drug resist-
ant pathogens (Donadio et al. 2010; Gwynn et al. 2010). 
Despite the need for new antibiotics with new modes of 
action, there has been a “discovery void”, where no new 
antibiotics were discovered between 1987 and 2011 
[though some drugs have been introduced to the market 
place, they were discovered much earlier (Silver 2011)].
Arguably the best source for new antibacterials has his-
torically been natural products, but efforts to exploit nat-
ural products as a source for new antibacterials has been 
in decline for many years (Brown et al. 2014). There are 
a number of contributing factors that have been postu-
lated to have caused this decline. Among these factors is 
the idea that the most abundant and effective antibacteri-
als have already been discovered and their relative abun-
dance masks and otherwise complicates the discovery of 
novel but more rare antibacterials (Brown et  al. 2014). 
Another often cited problem is that the high-throughput 
screening (HTS) of chemical libraries against specific and 
essential bacterial enzymes has not been as successful as 
hoped. While both natural products and HTS approaches 
have obvious merits, the development of new discovery 
approaches would be beneficial.
Previously, a biocatalytic approach for creating a 
library of indole based compounds was described, that 
focused primarily on isolating compounds with anti-
bacterial activity towards Mycobacterium tuberculosis 
(TB, McClay et  al. 2013). While exploring <1% of the 
theoretical chemical space that can be accessed with the 
described approach, 22 compounds were isolated that 
had minimum inhibitory concentrations (MIC) against 
TB of <2  µg/ml, with the most promising compound, 
SAB-P1, having a MIC of 0.16  µg/ml. It was also noted 
that a number of indole trimers, with varying degrees 
of potency towards TB, also had antibacterial activ-
ity towards many Gram-positive bacteria, which might 
make them more useful than the TB specific dimers. In 
this study, to gain a better understanding of the range 
of the indole based trimers that can be produced using 
combinatorial biocatalysis, and to assess their potential 
application as antibacterials, fermentation conditions 
were altered to favor the production of indole trimers. For 
this study, the only catalyst used was the I100V isoform 
of the toluene-4-monooxygenase of Pseudomonas men-
docina KR1 expressed in E. coli (McClay et al. 2013). The 
range of substrates provided to the catalyst was restricted 
to anthranil and selected derivatives of indole with pen-
dant substitutions. The compounds produced in good 
yield were screened for activity against the Gram-positive 
representatives of the ESKAPE pathogens group [Entero-
coccus faecalis and Staphylococcus aureus (Boucher et al. 
2009)] and some representatives of the National Institute 
of Allergy and Infectious Diseases (NIAID) priority path-
ogens group [Bacillus anthracis, Listeria monocytogenes, 
and Francisella tularensis (NIAID webpage)]. The HepG2 
liver cell line was used to determine mammalian tox-
icity. A number of trimers had MIC values of <2  µg/ml 
against multiple pathogens and a broad therapeutic win-
dow based on HepG2 toxicity. X-ray crystallography was 
used to solve the structure of six of the trimers produced. 
Structural data showed that the trimers described could 
be categorized into two groups, those that were trypt-
anthrin-like and those there were related to the natural 
product 2,2-bis(3-indolyl) indoxyl (BII). Of particular 
interest was the antibacterial compound SAB-J85, which 
has a structure that suggests that any number of com-
pounds with ring structures that can be oxidized by the 
I100V catalyst (or other oxygenases) could serve as useful 
substrates for combinatorial biocatalysis.
Materials and methods
Biotransformation conditions
The creation of the toluene-4-monooxygenase based 
biocatalyst (I100V), and the chemicals used have been 
described elsewhere (McClay et  al. 2013). However, the 
fermentation conditions used were modified to favor the 
production of indole based trimers by lowering the pH 
of the media used for the biotransformation as described 
below. To prepare the biocatalyst for the biotransfor-
mation reactions, a 10-ml culture of E. coli carrying 
the I100V oxygenase was grown overnight in LB broth 
amended with 25 μg/ml kanamycin. The starter culture 
was aseptically transferred to a 3-l fermentor filled to 80% 
capacity with basal salts medium [BSM (Hareland et  al. 
1975)]. Glucose (2  g/l) and kanamycin (25  µg/ml) were 
added to the medium, which was stirred at 200  rpm, at 
30°C, while maintaining the pH between 6.8 and 7.2 by 
the automated addition of sodium hydroxide. When 
the initial carbon source was consumed, as judged by a 
decrease in the rate of oxygen consumption, 2 g/l of glu-
cose was added and the expression of I100V was induced 
by adding sodium benzoate to a final concentration of 
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50 mg/l, followed by 6–8 h of additional growth. The cells 
were harvested via centrifugation and suspended in 2  l 
of BSM which had been amended with HCl to bring the 
pH down from ~7.2 to 6–5.5. The cells were then distrib-
uted as 250-ml aliquots to baffled 2-l Erlenmeyer flasks. 
The biotransformations were started by adding a total of 
20–30  mg of each substrate dissolved in 200–300  µl of 
ethanol along with 2 g/l of glucose and 50 mg/l of sodium 
benzoate. The biotransformation reactions were allowed 
to incubate overnight with shaking at 100  rpm at 30°C. 
The products of the biotransformation were harvested 
and purified as previously described (McClay et al. 2013).
Determination of MIC and MBC
Minimum inhibitory concentration experiments were 
performed with four Gram-positive bacterial strains. 
These include B. anthracis −Δ ANR strain (plasmid-
cured Ames strain of B. anthracis), E. faecalis (ATCC 
#29212), L. monocytogenes (ATCC #104035), S. aureus 
(ATCC #29213) and the Gram-negative F. tularensis 
(ATCC #43300). MIC values were determined by the 
microdilution method. LB media was added to each well 
in a row on a sterile 96-well flat bottom tissue culture 
plate. 96 µl of LB media was added to the first column and 
50 µl was added to all subsequent wells. The compounds 
to be tested were added to the first column for a final well 
volume of 100 µl. Compounds were then serially diluted 
(2-fold) across the columns of wells by pipetting and mix-
ing 50 µl of solution. The extra 50 µl was discarded from 
the final well. Ciprofloxacin was used as a control in these 
studies. Prior to setting up the MIC plates, the appropri-
ate bacterial cultures were grown to mid log-phase and 
subsequently diluted to an OD600 = 0.004 with fresh LB 
media. 50 µl of this bacterial culture was added to each 
well of the plate, and the plate was then incubated at 37°C 
overnight without shaking. The MIC value for each com-
pound represents the lowest concentration of the com-
pound that resulted in a clear well with no signs of visible 
growth. To determine the minimum bactericidal con-
centration (MBC), aliquots from clear wells containing 
increasing concentrations of the compound were plated 
onto antibiotic-free agar plates, and the lowest concen-
tration at which no visible growth was observed was 
reported as the MBC.
Cytotoxicity
The cytotoxicity of the test compounds was determined 
using the sulforhodamine B (SRB) assay (Vichai and Kir-
tikara 2006) in the human hepatoma cell line HepG2 
(ATCC #HB-8065). This assay directly measures cellular 
protein content. The HepG2 cells were seeded into 96 
well plates and incubated for 24  h with different con-
centrations of each of the test compounds. At the end 
of incubation period, cells were fixed with 10% (wt/v) 
trichloroacetic acid and stained for 30 min, followed by 
removal of excess dye by washing with 1% (v/v) acetic 
acid. The protein-bound dye was dissolved in 10  mM 
Tris base, and absorbance was determined by using 
a spectrophotometer set at 510  nm. The results were 
compared to the results obtained with untreated cells. 
A dose–response curve was obtained and IC50 values 
determined.
X‑ray crystallography
The compounds, purified as previously described 
(McClay et al. 2013), were dissolved in a minimum vol-
ume of acetone, typically 2–3  ml in a 25-ml screw cap 
glass vial. Crystal growth trials were initially conducted 
with the cap off. If results were unsatisfactory, the cap 
was placed over the vial and tightened as needed to 
slow the evaporation rate down to enable the growth of 
larger crystals. X-ray diffraction data was collected at 
the Advanced Photon source LS-CAT beamline 21-ID-D 
using a using a MAR 300 CCD detector. The integration 
of intensities and refinement of unit cell parameters and 
orientation matrix were carried out with the HKL2000 
(Otwinowski and Minor 1997) and XDS (Kabsch 2010) 
program packages. The structures were solved and 
refined using SHELX (Sheldrick 2007).
Results
Evaluation of biological activity
The four Gram-positive bacteria species, B. anthra-
cis (Δ-ANR strain), E. faecalis, L. monocytogenes, and 
S. aureus, were challenged with 75 test compounds. 28 
of these compounds displayed promising antibacte-
rial activity (Table  1) with many of these compounds 
being active against more than one strain tested. Four 
compounds (SAB-J3, SAB-J45, SAB-J51, and SAB-J76) 
were active against all four strains tested. Additionally, 
SAB-J3 was tested against the Gram-negative organism 
F. tularensis and found to have a MIC of 1.56 µg/ml. All 
of the compounds that were active against more than 
one bacterial strain were assayed against HepG2 cells to 
determine their toxicity towards mammalian cells. Most 
of these compounds were not found to be significantly 
cytotoxic, displaying a selectivity index >10 fold ([cyto-
toxicity]/[MIC]). SAB-J3 and SAB-J45 had the most 
favorable selectivity index ranging between 64 and 128 
fold for SAB-J3, and 16-64 fold for SAB-J45, depending 
on which bacterial species served as the target. As indi-
cated in Table 1, some of the compounds were not fully 
soluble in aqueous media at the highest concentrations 
tested (100 µg/ml), thus they were not toxic at the limit 
of their solubility, which might differ from the number 
reported.
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Structural characterization
The structure of six of the indole based trimers, bio-
catalytically produced under mildly acid conditions, 
were solved using X-ray crystallography. Three of 
these, SAB-7fR1, SAB-J78, and SAB-J83 are merely 
substituted isomers of SAB-R1, which has been previ-
ously reported (McClay et  al. 2013). The substitution 
pattern of these compounds directly reflects the sub-
stitution pattern of the substrates provided. Another 
substituted isomer of SAB-R1, SAB-R1-OH, contains 
an additional oxygen atom. The compound SAB-J85 is 
also structurally similar to SAB-R1, but, the pendant 
anthranil moiety is attached via a linkage between the 
six member ring of anthranil and C11 of tryptanthrin, 
as opposed the heterocyclic ring that was involved in 
all examples mentioned above. The structure of com-
pound, SAB-J50, is comprised of two indoles and 
one 1-methylindole. Excluding the pendant methyl 
group, the structure of SAB-J50 is identical to that of 
2,2-bis(3-indolyl) indoxyl (BII), which has been previ-
ously described (Veluri et al. 2003; Watsuji et al. 2007; 
Ganachaud et al. 2008).
Table 1 MIC, MBC and IC50 values (µg/ml) for selected compounds
The most effective compound against each strain shown in italic font.
na not applicable, nd not determined.
Substrate abbreviations: Ind indole, Ant anthranil, 4B 4-bromoindole, 5B 5-bromoindole, 5f 5-fluoroindole, 6F 6-fluoroindole, 7F 7-fluoroindole, 5C 5-chloroindole, 
6C 6-chloroindole, 7C 7-chloroindole, 1M 1-methylindole.
a Compounds partially insoluble at concentration listed.
Test compounds Substrate(s) MIC/MBC IC50
B. anthracis E. faecalis L. monocytogenes S. aureus HepG2
Ciproflaxin na 0.07 0.52 1.56 0.68 nd
Tryptanthrin na >25 nd nd 4.6 nd
SAB-R1 Ind(Ant) >12.5 >12.5 >12.5 >12.5 nd
SAB-C10 5C 3.12/12.5 12.5 12.5 6.25/25 >100
SAB-J2 5F 6.25 12.5 12.5 3.12/12.5 49.2
SAB-J3 5B 1.56/12.5 0.78/>25 1.56/>25 1.56/12.5 >100a
SAB-J7 5C(Ant) 6.25 >25 >25 >25 nd
SAB-J11 Ind(Ant) 3.12/25 >25 >25 6.25 >100
SAB-J16 5B 6.25 12.5 25 12.5 nd
SAB-J19 4B(7C) 6.25 >25 25 6.25 nd
SAB-J20 6C 6.25 >25 >25 6.25 nd
SAB-J22 5F(1M) 6.25 >25 >25 >25 nd
SAB-J25 6C(7C) 3.12/25 12.5 25 6.25 >100a
SAB-J35 4B 6.25 >25 >25 >25 nd
SAB-J36 6C 6.25 25 >25 12.5 nd
SAB-J37 5B(6C) 3.12/25 12.5 12.5 6.25 >100a
SAB-J38 5C(Ant) 3.12/12.5 >25 25 6.25 >100
SAB-J39 5C(Ant) 6.25 >25 >25 6.25 >100
SAB-J45 5B(Ant) 1.6/3.3 3.1 6.3 3.1/12.5 >100
SAB-7f-R1 7F(Ant) >12.5 >12.5 >125 3.1/>12.5 nd
SAB-J51 5F(7F) 0.88/4.69 1.95/>12.5 1.76/>12.5 1.17/>12.5 78.4a
SAB-J62 5F(Ant) 5.47/>12.5 >12.5 >12.5 5.47/>12.5 >100
SAB-J63 5B(Ant) 3.12/>12.5 >12.5 >12.5 5.4/>12.5 >100a
SAB-J65 5C(Ant) 2.15/>12.5 >12.5 >12.5 0.98/>12.5 >100
SAB-J69 5B(Ant) 3.52/>12.5 >12.5 >12.5 3.12/>12.5 >100
SAB-J76 6C(Ant) 0.78/2.34 2.73/>12.5 7.29/>12.5 2.15/12.5 43.8
SAB-J78 6C(Ant) 1.56/>12.5 >12.5 >12.5 3.9/>12.5 >100
SAB-J79 6C(Ant) 0.78/4.69 >12.5 >12.5 1.37/9.38 >100
SAB-J81 5B(Ant) >7.29 >12.5 >12.5 1.37/>12.5 >100
SAB-J82 5B(Ant) 6.25 >12.5 >12.5 6.25 nd
SAB-J85 6C(Ant) 0.78 nd nd 3.13 nd
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Discussion
To further explore the potential and utility of using com-
binatorial biocatalysis to create novel compounds with 
useful biological activity, fermentations were conducted 
under mildly acidic starting conditions (pH 6) to favor 
the production of indole based trimers (Figure  1). Pre-
vious work had shown that while indole based dimers 
produced using combinatorial biocatalysis were effec-
tive against M. tuberculosis, indole trimers had a broader 
spectrum of activity (McClay et al. 2013) and ultimately 
might be more useful. The trimers characterized here fell 
into two broad categories, those with a tryptanthrin-like 
structure and those with a 2,2-bis(3-indolyl) indoxyl (BII) 
like structure.
Tryptanthrin (Figure  2) is an intriguing molecule that 
holds promise for treating a number of disease states 
including cancer (Liao et  al. 2013; Chan et  al. 2009; Jao 
et al. 2008), malaria (Bhattacharjee et al. 2002), sleeping 
sickness (Bakshi et  al. 2009), toxoplasmosis (Krivogor-
sky et  al. 2008), and leishmaniasis (Bhattacharjee et  al. 
2002). Furthermore, studies have shown that certain 
tryptanthrin derivatives are effective antibacterial agents 
against both E. coli (Bandekar et al. 2010) and M. tuber-
culosis (Hwang et  al. 2013) in  vitro. In previous studies 
the most potent derivatives of tryptanthrin active against 
E. coli, TB, malaria, trypanosomiasis, and toxoplasmosis 
have pendant halo- or nitro substitutions at position 8 of 
tryptanthrin [though other substitution can also be pre-
sent (Bandekar et al. 2010; Hwang et al. 2013; Scovill et al. 
2002; Krivogorsky et  al. 2008)]. A mechanism of action 
for tryptanthrin and its derivatives has not been firmly 
established though an in silico study suggested that trypt-
anthrins might function as inhibitors of the enoyl-acyl 
carrier protein reductase InhA (Tripathi et al. 2012). It is 
worth noting that in vivo, tryptanthrins failed to reduce 
the M. tuberculosis burden in mice, perhaps due to poor 
absorption and/or rapid elimination (Hwang et al. 2013).
In this study, a new class of tryptanthrin-like com-
pounds was isolated and identified. All of the trypt-
anthrin-like compounds for which a structure was 
determined shared two characteristics. First, they all had 
pendant substitutions at position number 11 (Figure  2). 
Second, they all had an intense red/orange color easily 
visible on TLC plates. The first compound of this class 
that was isolated was, SAB-R1, which was previously 
described in McClay et al. (2013). SAB-R1, derived from 
un-substituted indole and anthranil, did not have appre-
ciable antibacterial activity against the four organisms 
tested here (MIC > 25 µg/ml) or Mtb. However, isomers 
of SAB-R1 derived from indole isomers with various 
halogen substitutions around the aromatic ring have a 
much higher degree of antibacterial activity, in line with 
previous studies mentioned above where various substi-
tutions at position 8 resulted in more efficacious com-
pounds. Both the position and size of the substituting 
halogen seem to impact both the MIC and the spectrum 
of activity of the antibacterial compounds. The SAB-R1 
derivatives that resulted from combining anthranil with 
5-fluoroindole (SAB-J83) and 7-fluoroindole (SAB-7f-R1) 
had better MIC values than SAB-R1, but SAB-7f-R1 was 
~4 times as effective against S. aureus (MIC  =  3.1  µg/
ml) as was the SAB-J83 (Table 1). The compound derived 
from 6-chloroindole (SAB-J78) was equally effective 
against S. aureus as was SAB-7f-R1, but was more effec-
tive against B. anthracis (MIC  =  1.56  µg/ml). Finally, 
SAB-J45, the putative SAB-R1 isomer derived from 
5-bromoindole (based on TLC and LC/MS analysis in the 
absence of crystal structure data) was effective against all 
four organisms tested here with MIC values ranging from 
1.6 to 6.3 µg/ml.
Molecular weight analysis indicated that many of the 
orange compounds that migrated more slowly during 
TLC separation had molecular weights consistent with 
them being SAB-R1 derivatives carrying an additional 
oxygen atom. The crystal structures of SAB-R1-OH and 
SAB-J85 show that the additional oxygen groups can be 
attached either directly to carbon 11 of the tryptanthrin 
portion of the compound (SAB-R1-OH, which was not 
Dimers
Trimers
Figure 1 The effect decreased pH has on the product distribution 
during combinatorial biocatalysis. In each case the catalyst was the 
I100V isoform of T4MO and the two substrates were anthranil and 
6-chloroindole. The pH values shown are the values for the media 
prior to adding cells and substrates, the pH at the end of the reac-
tions was not measured.
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tested for antibacterial activity because of limited supply), 
or indirectly via the pendant group as is the case with 
SAB-J85. The compound SAB-J85 is a particularly inter-
esting compound that resulted from the polymerization 
of 2 anthranils and 1 indole. Unlike all of the other trypt-
anthrin-like compounds described here, which are linked 
via the highly reactive C3 of indole and the C11 of trypt-
anthrin, SAB-J85 is linked via the comparatively inert 
6-member ring of anthranil. It is of interest to note that 
the two compounds, SAB-J85 and the more hydrophobic 
compound SAB-J78, differ only in the makeup of their 
pendant groups, yet they have very similar MIC values 
for the two organisms that were challenged with both 
compounds. This implies that the antibacterial activity of 
these compounds might be in part or in whole associated 
with the tryptanthrin portion of the molecule. If such is 
the case, the entirety of the pendant group might be a 
substrate for further modifications that could impact the 
absorption and distribution of the compounds.
In addition to the tryptanthrin-like compounds men-
tioned above, the other group of antibacterial indole 
trimers described in this study are believed to be ana-
logs of the compound BII (Figure  2). However, most of 
these putative BII analogs did not crystallize under the 
Figure 2 Structure of key compounds mentioned in text.
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conditions described, making X-ray crystallography 
impossible. The conclusion that they have the same core 
structure as BII is based on a number of lines of evidence. 
First, it has been previously shown that BII can be formed 
by a laccase catalyzed oxidation of indole (Ganachaud 
et al. 2008). Second, the crystal structure of SAB-J50 (Fig-
ure 2), is identical to BII, excluding the pendant methyl 
group. Finally, all of the other putative representatives 
of this compound class had molecular weights, spectral 
and fluorescent characteristics, and TLC migration pat-
terns that were consistent with being of the same chem-
otype as SAB-J50. BII is a natural product produced by 
the Bacillus symbiont, Symbiobacterium thermophilum 
(Watsuji et al. 2007) and functions as a reversible growth 
inhibitor of both the Gram-negative S. thermophilum 
(MIC  =  12  µg/ml) and Gram-positive Rhodococcus sp. 
strain RHA1 (MIC  =  4  μg/ml), but was not effective 
against 12 other bacterial species at >14  µg/ml, includ-
ing B. subtilis 168. Previously, SAB-C10, the presumptive 
isomer of BII derived from 5-chloroindole, was described 
and it was noted that SAB-C10 was effective against B. 
subtilis 168 (as well as B. cereus, E. faecalis, M. smegma-
tis, S. epidermidis, and C. acetobutylicum) at <4  µg/ml 
(McClay et al. 2013). This work expanded on those find-
ings creating new fluoro-, chloro-, and bromo-derivatives 
of BII (SAB-J2, -J3, -J51, and -J76), which along with 
SAB-C10 were tested against the suite of Gram-positive 
organisms (Table 1). The 5-bromo-derivative of BII (SAB-
J3) had the best activity profile inhibiting all of the patho-
gens at 1.56 µg/ml or below, while having no observable 
cytotoxicity for HepG2 cells at the limits of its solubil-
ity. Two other derivatives of BII, SAB-J51, (derived from 
a mixture of 5-chloro- and 7-chloroindole) and SAB-
J76 (derived from 6-chloroindole) had comparable MIC 
values to SAB-J3. However, SAB-J51 proved to be less 
soluble than SAB-J3 and SAB-J76 appeared to be more 
cytotoxic for HepG2 cells. Although not all possible halo-
genated derivatives of BII have been isolated and tested, 
it appears that as is the case with the tryptanthrin-like 
compounds, incorporation of larger halogens appears 
to increase the antibacterial activity, though positional 
effects are important too.
The data presented here further demonstrate that com-
binatorial biocatalysis is a useful tool for generating novel 
compounds with potentially useful biological activity. In 
this case novel derivatives of tryptanthrin-like and BII-like 
compounds with significant antibacterial activity were 
created, with the halogenated derivatives being supe-
rior to the non-halogenated compounds both in activity 
spectrum and in vitro efficacy. One of the more interest-
ing compounds characterized here was the BII deriva-
tive produced from 3 5-bromoindoles (SAB-J3), which 
consistently had among the lowest MIC values with all of 
the Gram-positive organism tested and was also effective 
against the Gram-negative F. tularensis (MIC = 1.56 µg/
ml). While the existence of unsubstituted BII and its 
antibacterial properties towards both Gram-positive and 
Gram-negative organisms have been reported periodi-
cally (Bell et al. 1994; Ganachaud et al. 2008; Sheinkman 
et  al. 1978; Stull et  al. 1995; Watsuji et  al. 2007) to the 
best of our knowledge, this is the first report of the syn-
thesis of substituted derivatives of BII and their improved 
antibacterial properties. Another interesting compound 
described herein is SAB-J85. The synthesis of SAB-J85, 
with the linkage of the six member ring of anthranil to 
position 11 of tryptanthrin suggests that any number of 
precursors with ring structures that can be activated by 
oxygenases could be used to create new tryptanthrin-like 
compounds. As a consequence of the oxygenase catalyzed 
activation, the new derivatives would likely also have a 
free hydroxyl group which would serve as a convenient 
site for further modification to help influence the absorp-
tion, metabolism, distribution, and excretion characteris-
tic of the therapeutic compound. Tryptanthrin, BII, and 
improved derivatives thereof have not been distributed on 
a commercial scale for application as antibacterial agents, 
and thus, they might represent attractive scaffolds for 
developing new antibacterials.
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